RSRyosuke Shinouchi

Ryosuke Shinouchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryosuke Shinouchi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Koji Nobe

    Department of Pharmacology, Showa Medical University Graduate School of Pharmacy (R.S.; K.S.; K.N.), 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; Pharmacological Research Center, Showa Medical University (R.S.; K.S.; K.N.), 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

    3 shared publications
  • Akiko Sasaki

    Department of Pharmacology, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; Pharmacological Research Center, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

    2 shared publications
  • Jay P. McLaughlin

    Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, USA

    2 shared publications
  • Keiji Hasumi

    Department of Applied Biological Science, Tokyo University of Agriculture and Technology, 3-5-8 Saiwaicho, Fuchu, Tokyo 183-8509, Japan

    2 shared publications
  • Keita Shibata

    Department of Pharmacology, Graduate School of Pharmacy, Showa University, Tokyo 142-8555, Japan

    2 shared publications
  • Koji Nobe

    Department of Pharmacology, Graduate School of Pharmacy, Showa University, Tokyo 142-8555, Japan

    2 shared publications

Latest Publications

  • Open Access

    Human α1-Antitrypsin Inhibits Nociceptor Excitability and Relieves Inflammatory and Neuropathic Pain

    by Alaina L. Waters, Santiago Loya-López, Erick J. Rodriguez-Palma, Shainnel O. Eans, Ryosuke Shinouchi, Jordan Stokes, Jay P. McLaughlin, Sihong Song, Rajesh Khanna

    Chronic pain affects hundreds of millions of people and remains poorly managed, as the most effective drugs, including opioids, carry side effects that limit long-term use. Because inflammation drives both the initiation and maintenance of chronic pain, anti-inflammatory mechanisms are an attractive analgesic target. We investigated human alpha-1 antitrypsin (hAAT), a serine proteinase inhibitor with potent anti-inflammatory activity and established protection across disease models, as a candidate analgesic, using Aralast NP®, a clinical-grade, already-approved formulation that makes findings directly translatable. Using calcium imaging and patch-clamp electrophysiology in mouse dorsal root ganglion (DRG) neurons, we found that hAAT reduced activation of low-voltage-activated Ca2+ channels and dampened intrinsic excitability. Veratridine-evoked Ca2+ responses, a sodium-channel-dependent readout of nociceptor activity, were suppressed by hAAT to a degree comparable to the selective sodium channel inhibitors ProTx-II (NaV1.7) and VX-548 (NaV1.8), driven by loss of the nociceptor-associated response profiles. In vivo, hAAT decreased pain sensitivity and pain-associated behaviors in both inflammatory and neuropathic models. Together, these findings reveal a mechanism by which hAAT suppresses nociceptor activity and position Aralast NP® as a safe, effective candidate for treating chronic pain.

  • Open Access

    Characterization of Novel Sigma Receptor Ligands Derived from Multicomponent Reactions as Efficacious Treatments for Neuropathic Pain

    by Ryosuke Shinouchi, Bengisu Turgutalp, Rohini S. Ople, Shainnel O. Eans, Ashai K. Williams, Haylee R. Hammond, Andras Varadi, Rebecca Notis Dardashti, Susruta Majumdar, Jay P. McLaughlin

    Background/Objectives: Neuropathic pain remains a significant clinical challenge, with current treatments often providing inadequate relief and adverse effects. Sigma receptors (SRs) modulate nociception and have emerged as potential therapeutic targets for neuropathic pain. Although putative sigma-1 receptor (S1R) ligands have demonstrated analgesic efficacy in preclinical models, their in vivo efficacy and safety profiles require further clarification. Methods: Analogs of well-known selective S1R ligand UVM147 were synthesized using 3-component Ugi reactions and examined in vitro for receptor affinity in radioligand competition binding assays and in vivo with mouse models of neuropathic and inflammatory pain and adverse effects. Results: Three novel heterocyclic compounds (RO-4-3, RO-5-3, and RO-7-3) displayed in vitro nanomolar affinity with varying selectivity for both SR subtypes (S1R and S2R). When screened in vivo at a dose of 30 mg/kg s.c. in mice first subjected to chronic constriction injury (CCI), RO-5-3 and RO-7-3 possessed anti-allodynic potential, while UVM147 was inactive. Upon full characterization, RO-5-3 significantly attenuated mechanical allodynia in a dose-dependent manner, while RO-7-3 was ineffective at higher doses. Both compounds dose-dependently attenuated nociceptive behaviors in the mouse formalin assay. RO-5-3 induced mild respiratory depression without impairing locomotor activity, whereas RO-7-3 caused transient respiratory depression and locomotor impairment. Additionally, RO-5-3, but not RO-7-3, induced conditioned place aversion consistent with potential S2R involvement. Conclusions: RO-5-3 exerts antinociceptive and anti-allodynic effects with minimal adverse behavioral effects, supporting the role of SRs in pain modulation. These results add to growing evidence supporting the development of SR ligands as efficacious therapeutics for neuropathic pain with fewer clinical liabilities.


  • The effect of hand therapy on alleviating chemotherapy-induced peripheral neuropathy in a model mouse

    by Ryosuke Shinouchi, Akiko Sasaki, Takashi Takaki, Mayumi Tsuji, Yuji Kiuchi, Koji Nobe


  • Open Access

    SMTP-44D Exerts Antioxidant and Anti-Inflammatory Effects through Its Soluble Epoxide Hydrolase Inhibitory Action in Immortalized Mouse Schwann Cells upon High Glucose Treatment

    by Ryosuke Shinouchi, Keita Shibata, Shiori Jono, Keiji Hasumi, Koji Nobe

    Diabetic neuropathy (DN) is a major complication of diabetes mellitus. We have previously reported the efficacy of Stachybotrys microspora triprenyl phenol-44D (SMTP-44D) for DN through its potential antioxidant and anti-inflammatory activities. However, the mechanisms underlying the antioxidant and anti-inflammatory activities of SMTP-44D remain unclear. The present study aimed to explore the mechanism of these effects of SMTP-44D in regard to its inhibition of soluble epoxide hydrolase (sEH) in immortalized mouse Schwann cells (IMS32) following high glucose treatment. IMS32 cells were incubated in a high glucose medium for 48 h and then treated with SMTP-44D for 48 h. After incubation, the ratio of epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETs), oxidative stress markers, such as NADPH oxidase-1 and malondialdehyde, inflammatory factors, such as the ratio of nuclear to cytosolic levels of NF-κB and the levels of IL-6, MCP-1, MMP-9, the receptor for the advanced glycation end product (RAGE), and apoptosis, were evaluated. SMTP-44D treatment considerably increased the ratio of EETs to DHETs and mitigated oxidative stress, inflammation, RAGE induction, and apoptosis after high glucose treatment. In conclusion, SMTP-44D can suppress the induction of apoptosis by exerting antioxidant and anti-inflammatory effects, possibly through sEH inhibition. SMTP-44D can be a potential therapeutic agent against DN.


  • Open Access

    The Effect of Hand Therapy on Alleviating Chemotherapy-Induced Peripheral Neuropathy in a Model Mouse

    by Ryosuke Shinouchi, Akiko Sasaki, Takashi Takaki, Mayumi Tsuji, Yuji Kiuchi, Koji Nobe

    The use of neurotoxic chemotherapeutic agents induces numbness in the limbs through chemotherapy-induced peripheral neuropathy (CIPN). Recently, we found that hand therapy involving finger massage improved mild to moderate numbness in CIPN patients. In this study, we behaviorally, physiologically, pathologically, and histologically investigated the mechanisms underlying hand therapy-induced numbness improvement in a CIPN model mouse. Hand therapy was performed for 21 days after the disease induction. Its effects were evaluated using mechanical and thermal thresholds and blood flow in the bilateral hind paw. Moreover, 14 days after the hand therapy was administered, we assessed the blood flow and conduction velocity in the sciatic nerve, the level of serum galectin-3, and the histological myelin and epidermis-related changes in the hindfoot tissue. Hand therapy significantly improved allodynia, hyperalgesia, blood flow, conduction velocity, serum galectin-3, and epidermal thickness in the CIPN model mouse. Furthermore, we observed the images of repairs of the myelin degeneration. Thus, we found that hand therapy could improve numbness in the CIPN model mouse and that it could help to repair peripheral nerves by promoting blood circulation in the limbs.

  • Open Access

    SMTP-44D improves diabetic neuropathy in mice

    by Ryosuke Shinouchi, Keita Shibata, Shiori Jono, Terumasa Hashimoto, Keiji Hasumi, Koji Nobe

    Diabetic neuropathy (DN) is one of the major complications of the diabetes and has a prevalence as high as 50 % of diabetic patients. However, there are few approved effective therapies against painful or insensate DN. In the present study, we evaluated the effect of SMTP-44D in mice model of DN. SMTP-44D (0.3, 3 and 30 mg/kg) was administered to 200 mg/kg streptozotocin (STZ)-induced diabetic mice from the 1st to the 4th weeks after the injection of STZ. The effect of SMTP-44D was evaluated by mechanical allodynia, thermal hyperalgesia, and velocity of conduction and blood flow of sciatic nerve. Furthermore, levels of inflammatory cytokines and oxidative stress in sciatic nerve by administration of SMTP-44D were assessed by ELISA and TBARS assay, respectively. To assess neurological degeneration, the G-ratio and the myelin thickness of Schwann cells in the sciatic nerve were measured. The treatment with SMTP-44D dose-dependently ameliorated allodynia, hyperalgesia, and velocity of conduction and blood flow of sciatic nerve in diabetic mice of DN. Furthermore, levels of inflammatory factors were also improved. These results indicate that SMTP-44D shows potential as a new therapeutic agent for DN.